- This event has passed.
MET Inhibition in Metastatic NSCLC “In the Spotlight”
September 10 @ 18:30 - 19:30 SMT
Supported by an independent educational grant from the healthcare business of Merck KGaA, Darmstadt, Germany.
Program Description
Join us for an exciting dinner event, as we discuss incorporating MET inhibitors into critical treatment decisions. This CME-accredited dinner symposium will cover evidence-based, consensus-guided recommendations and the latest data from completed and ongoing clinical trials demonstrating the application of MET inhibitors in the treatment of NSCLC. Our goal for this event is to further the adoption of best practices for patient selection and molecular profiling as well as guide consideration for global regulatory approvals and data that may show how MET inhibitors could overcome aberrant EGFR TKI treatment resistance. Take a peek at the agenda below, and reserve your spot today!
To reserve your seat, sign up on ReachMD.com/MET
Agenda:
18:15
Doors Open, Dinner & Registration
18:30
Welcome and Introductions
18:33
Have you MET Gene Aberrations in NSCLC?
Featuring a Pathologist’s Perspective by Keith Kerr, BSc, MB, ChB
18:38
Panel Discussion and Question & Answer
18:46
Have you MET the New Molecular-Driven Therapies in NSCLC?
18:56
Panel Discussion and Question & Answer
19:04
Have you MET NSCLC in Clinical Practice?
19:14
Panel Discussion and Question & Answer
19:22
Our Message Worth Sharing: Key Takeaways
19:28
Closing Remarks
Speakers
Paul K. Paik, MD
Clinical Director, Thoracic Oncology Service
Memorial Sloan Kettering Cancer Center
New York, NY, United States
D. Ross Camidge, MD, PhD
Director, Thoracic Oncology
University of Colorado
Aurora, CO, United States
Resources
To reserve your seat, sign up on ReachMD.com/MET